Two Peptides, Two Different Jobs
CJC-1295 and ipamorelin are among the most frequently compared research peptides in the growth-hormone-secretagogue literature, and they are frequently studied together precisely because they act on different receptors through different mechanisms. Understanding that distinction is the starting point for any Canadian laboratory designing a study around either compound. This guide compares their structures, mechanisms, half-lives, and published research context — strictly as an in vitro / preclinical reference, not as guidance for human use.
For the deeper single-compound background, see the CJC-1295 DAC vs No DAC guide, the CJC-1295 encyclopedia entry, and the ipamorelin encyclopedia entry.
The Core Mechanistic Difference
The two peptides sit on opposite sides of the growth-hormone signalling axis:
- CJC-1295 is a GHRH analog. It mimics growth-hormone-releasing hormone and binds the GHRH receptor on the pituitary, acting on the same pathway the body uses to stimulate growth-hormone synthesis and release. It increases the *amount* of hormone available per pulse.
- Ipamorelin is a GHRP (growth-hormone-releasing peptide) and a ghrelin-receptor agonist. It binds the GHS-R1a receptor — the ghrelin receptor — to trigger release, and it is noted in the literature for being highly selective, with minimal reported effect on cortisol or prolactin in preclinical models compared with older GHRPs such as GHRP-6.
Because they act on two separate receptors, the research rationale for studying them in combination is that the signals are complementary rather than redundant — a recurring theme in the secretagogue literature.
Structure and Half-Life at a Glance
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRP / ghrelin-receptor agonist |
| Receptor | GHRH receptor | GHS-R1a (ghrelin receptor) |
| Amino acids | 29 (30 with DAC linker) | 5 (pentapeptide) |
| Half-life (no DAC) | ~30 minutes | ~2 hours |
| Half-life (with DAC) | ~6–8 days | not applicable |
| Selectivity note | acts on GHRH pathway | selective; low reported cortisol/prolactin effect |
The half-life column is where the DAC (Drug Affinity Complex) modification matters most. Non-DAC CJC-1295 (often labelled "mod GRF 1-29") clears in about 30 minutes, while the DAC version binds serum albumin and extends the half-life to roughly 6–8 days — a ~300-fold difference covered in detail in the DAC vs No DAC guide. Ipamorelin has no long-acting analog; its ~2-hour half-life is intrinsic to the molecule.
Why the Research Literature Pairs Them
The preclinical rationale for co-administration in study designs is mechanistic synergy:
- Different receptors, additive signal. A GHRH analog and a ghrelin-receptor agonist stimulate release through separate pathways, and published secretagogue work reports the combined signal exceeding either alone in animal models.
- Ipamorelin's selectivity. Older GHRPs raised cortisol and prolactin in preclinical studies; ipamorelin's reported selectivity is the reason it, rather than GHRP-6, is the common pairing partner for CJC-1295 in the literature.
- Complementary kinetics. CJC-1295's longer footprint (especially with DAC) and ipamorelin's shorter, sharper action are studied together as a way to characterize both baseline and pulsatile signalling in the same model.
This is descriptive of the *research literature and mechanism only.* Nothing here is a protocol, a dose, or guidance for administration to humans or animals.
Choosing Between Them for a Study Design
Which compound a Canadian research buyer selects depends entirely on the experimental question:
- Studying the GHRH pathway specifically? CJC-1295 is the GHRH-side tool. The DAC vs no-DAC decision then hinges on whether the design needs a long, steady exposure (DAC) or short, controlled pulses (no DAC).
- Studying the ghrelin-receptor / GHS-R1a pathway? Ipamorelin is the selective probe, useful precisely because it isolates that receptor with low off-target cortisol/prolactin activity in preclinical reports.
- Characterizing combined secretagogue signalling? The literature's pairing of both is the reason many laboratories stock them together.
For related growth-axis compounds, the sermorelin and tesamorelin encyclopedia entries cover other GHRH-analog research tools, and IGF-1 LR3 sits downstream of the growth-hormone axis.
Handling, Reconstitution, and Storage
Both compounds ship lyophilized and require reconstitution before laboratory use. The mechanics are identical to any other peptide in this class:
- Reconstitute with quality bacteriostatic water — diluent quality affects solution integrity as much as the peptide's own purity, covered in the bacteriostatic water guide.
- Follow the step-by-step peptide reconstitution guide for concentration math and technique.
- Store per the peptide storage guide: lyophilized powder and reconstituted solution have very different stability windows.
Verifying What You Actually Received
For either peptide, the batch's Certificate of Analysis is the artifact that separates a labelled purity claim from a measured one. Independent third-party HPLC and mass-spec testing — not an in-house number — is the standard Canadian research buyers should expect. See /lab-reports for published batch documentation and the Canadian sourcing guide for the full vendor-vetting framework.
You can buy CJC-1295 DAC domestically in Canada from the Lux BioPure catalog; browse the full shop for the current in-stock growth-research peptides.
Frequently Asked Questions
What is the main difference between CJC-1295 and ipamorelin? CJC-1295 is a GHRH analog that binds the growth-hormone-releasing-hormone receptor, while ipamorelin is a ghrelin-receptor (GHS-R1a) agonist. They stimulate the growth-hormone axis through two separate receptors, which is why the research literature often studies them together rather than as substitutes.
Why are CJC-1295 and ipamorelin studied together? Because they act on different receptors, their signals are complementary rather than redundant in preclinical models. Ipamorelin's reported selectivity — low cortisol and prolactin effect versus older GHRPs — makes it the common pairing partner for CJC-1295 in the secretagogue literature.
Is ipamorelin more selective than other GHRPs? In published preclinical work, ipamorelin shows minimal effect on cortisol and prolactin compared with earlier growth-hormone-releasing peptides such as GHRP-6. That selectivity is the main reason it is favoured as a research probe for the ghrelin-receptor pathway specifically.
Does ipamorelin have a long-acting version like CJC-1295 DAC? No. The DAC (Drug Affinity Complex) modification that extends CJC-1295's half-life to roughly 6–8 days applies only to CJC-1295. Ipamorelin has an intrinsic half-life of about two hours with no long-acting analog.
Research Disclaimer
This article is a research reference for in vitro and preclinical laboratory contexts only. CJC-1295, ipamorelin, and every compound referenced are not approved for human or veterinary therapeutic use by Health Canada or any regulatory authority. Nothing here constitutes medical advice, dosing guidance, or a recommendation for administration to humans or animals.